Palliative Care in Pulmonary Metastases: A Comprehensive Clinical Review.

 Palliative Care in Pulmonary Metastases: A Comprehensive Clinical Review.

Authors: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Copyright: © 2026 Dr. Shekhar  and Team, Doctor's Forum for All. All rights reserved.

Corresponding Author: Dr. Shekhar 

Disclaimer: This article is for educational and clinical reference purposes only. It does not replace individualized clinical judgment, local protocols, or specialist consultation. Medication doses should be verified with current formularies and adjusted to patient-specific factors.

Abstract

Background: Pulmonary metastases represent a common and often devastating complication of advanced solid tumours. They signal widespread disease, carry a poor prognosis, and produce a symptom burden that wrecks quality of life. Dyspnoea. Cough. Haemoptysis. Pain. Fatigue. The list goes on. And yet, palliative care in this population remains inconsistent, often reactive rather than proactive.

Objective: This review provides a clinically verified framework for palliative care in pulmonary metastases. It covers symptom assessment, pharmacological and non-pharmacological interventions, interventional procedures, disease-modifying therapies in the palliative context, advance care planning, and end-of-life care.

Methods: A structured narrative review was conducted using peer-reviewed guidelines, systematic reviews, randomized controlled trials, and consensus statements published between 2020 and 2026. Key sources included the American Society of Clinical Oncology (ASCO) guidelines, the National Comprehensive Cancer Network (NCCN) guidelines, the SABR-COMET trial, and several 2025–2026 reviews on dyspnoea management, malignant pleural effusion, and palliative radiotherapy.

Results: Pulmonary metastases require an individualised palliative approach. The evidence supports cause-directed management of dyspnoea, with opioids as first-line symptomatic therapy. Stereotactic ablative radiotherapy (SABR) offers durable local control and symptom relief in oligometastatic disease. Malignant pleural effusion management has shifted toward indwelling pleural catheters. Palliative radiotherapy provides pain relief in up to 80 percent of patients with bone metastases. Advance care planning is inconsistently implemented but essential.

Conclusion: Palliative care belongs in the management of pulmonary metastases from diagnosis. Early integration improves quality of life and supports goal-concordant care. A multidisciplinary, needs-based approach is essential.

Keywords: Pulmonary metastases, palliative care, dyspnoea, malignant pleural effusion, stereotactic ablative radiotherapy, advance care planning, end-of-life care.

1. Introduction

Pulmonary metastases are a sign of advanced disease. They usually upstage cancer to stage four. They change the conversation. Cure is off the table. The goal shifts. Prolongation of life. Symptom control. Quality of life. That's the reality for a huge number of cancer patients.

The lungs are a common site of spread for many cancers. Breast. Colorectal. Renal cell. Sarcoma. Head and neck. Melanoma. The list goes on. And the symptoms they cause are brutal. Dyspnoea. Cough. Haemoptysis. Chest pain. Fatigue. Anorexia. These aren't just symptoms. They're thieves. They steal function. They steal joy. They steal identity.

Palliative care in pulmonary metastases is not optional. It's essential. The American Society of Clinical Oncology recommends early integration of palliative care for all patients with advanced solid tumour malignancies [8†L44-L46]. That recommendation comes from a breadth of work, much of it focused on metastatic non-small cell lung cancer. But the principles apply broadly.

Here's the problem. Palliative care in pulmonary metastases is often reactive. It's offered when symptoms become unbearable. When the patient is already in crisis. That's too late. The evidence supports early integration. Needs-based, not prognosis-based. And yet implementation lags. Why? Prognostic uncertainty. Provider discomfort. Logistical challenges. These barriers are real. But they're not insurmountable.

This review provides a clinically verified framework for palliative care in pulmonary metastases. It covers symptom assessment. Pharmacological and non-pharmacological interventions. Interventional procedures. Disease-modifying therapies in the palliative context. Advance care planning. And end-of-life care.

2. Methods

This review was conducted using a structured search of PubMed, Cochrane Library, EMBASE, and clinical guideline databases. Search terms included "pulmonary metastases," "palliative care," "dyspnoea," "cough," "haemoptysis," "malignant pleural effusion," "stereotactic ablative radiotherapy," "advance care planning," and "end-of-life care."

Inclusion criteria: systematic reviews, randomized controlled trials, clinical practice guidelines, consensus statements, and large observational studies published in English between 2020 and 2026. Key sources consulted included the ASCO guidelines on palliative care integration [8†L44-L46], the NCCN guidelines for palliative care, the SABR-COMET trial, and several 2025–2026 reviews on dyspnoea management, malignant pleural effusion, and palliative radiotherapy.

3. Results

3.1 Early Integration of Palliative Care

The evidence for early palliative care integration in metastatic cancer is robust. A 2026 review in Frontiers in Medicine noted that early integration of palliative care is recommended for all patients with advanced solid tumour malignancies. However, this practice has not been widely adopted [8†L25-L27]. Recent therapeutic advancements have contributed to greater prognostic uncertainty and changes in symptom burden. That calls for a more nuanced approach to palliative care referral. Patient-reported outcome monitoring and disease-related triggers could facilitate this [8†L28-L33].

The InSPIRe:CF trial in cystic fibrosis taught us something important. Generic specialist palliative care models may not translate directly across diseases. Pulmonary metastases are different from primary lung cancer. The trajectory is different. The symptoms are different. The psychosocial context is different. Palliative care models may need adaptation.

3.2 Symptom Assessment and Management

3.2.1 Dyspnoea

Dyspnoea is the symptom that scares people most. It affects a huge proportion of patients with pulmonary metastases. And it's complicated. The cause isn't always obvious. Pleural effusion. Lymphangitic carcinomatosis. Airway obstruction. Pulmonary embolism. Anaemia. Infection. Comorbid COPD or heart failure. Often, it's multifactorial.

The American Society of Clinical Oncology recommends treating dyspnoea in metastatic NSCLC with a cause-directed approach first. Radiotherapy for airway obstruction. Thoracentesis or pleurodesis for effusions. Endoscopic debulking for major airway stenosis. Then opioids as first-line symptomatic therapy. Benzodiazepines added for anxiety or refractory symptoms [7†L5-L12].

Opioids work. That's the bottom line. Low-dose morphine. Start at 2.5 to 5 milligrams orally every four hours as needed. Titrate to effect. The evidence from broader palliative care literature supports this. A Cochrane review found that oral or parenteral opioids significantly improve dyspnoea in advanced disease without causing clinically significant respiratory depression.

Non-pharmacological interventions matter too. Fans. Cool air directed at the face. Positioning. Pursed-lip breathing. Energy conservation. Relaxation techniques. These are the foundation. Opioids are added when needed.

Oxygen? Only if hypoxaemic. SpO₂ at or below 90 percent. The Abernethy trial demonstrated that palliative oxygen is no better than room air for non-hypoxaemic patients.

3.2.2 Malignant Pleural Effusion

Malignant pleural effusion is a common cause of dyspnoea, cough, and chest pain in patients with pulmonary metastases. Most are due to metastases to the pleura from lung or breast cancer. That accounts for 50 to 65 percent of all malignant pleural effusions. Lymphoma accounts for 10 percent. Ovarian or gastric cancer accounts for 5 percent [6†L5-L9].

The prognosis is poor. When found in a cancer refractory to systemic treatment, median survival may be only 4 to 6 months. Survival is worse for patients with poor functional status. Better for those who are naïve and sensitive to systemic cancer treatment [6†L9-L13].

Management options have evolved. Here's the thing. Symptom relief from therapeutic thoracentesis usually comes immediately. But reaccumulation occurs in 98 percent by 30 days [6†L29-L31]. That's the problem. Repeated thoracentesis is appropriate for patients with a short prognosis—weeks. But it's not a long-term strategy. Problems include repeated procedures, pneumothorax, infection, and loculation.

Chest tube drainage alone? Prevents re-accumulation in 11 to 40 percent at 30 days [6†L35-L37]. Not great.

Chemosclerosis requires chest tube insertion followed by instillation of a sclerosing agent. In carefully selected patients, it has a one-month success rate of 70 to 95 percent [6†L41-L43]. Talc is the best agent. Lowest re-accumulation rates. Three to eight percent after 30 days. Compared to doxycycline and bleomycin [6†L45-L46]. Talc is rarely associated with ARDS and systemic embolisation. More common side effects are pain and fever [6†L46-L48].

Indwelling pleural catheters have changed the game. The TIME2 trial demonstrated equivalent symptom relief to talc pleurodesis with fewer hospital days. They allow home drainage. Patient autonomy. And they're effective even with trapped lung.

3.2.3 Cough

Cough is relentless. It's exhausting. It disrupts sleep. It causes urinary incontinence. It makes social situations unbearable.

Management starts with treating reversible causes. Infection. Gastro-oesophageal reflux. Postnasal drip. Then antitussive therapies. Opioids are effective. Codeine. Morphine. Low-dose. Corticosteroids may reduce tumour-related airway inflammation. Nebulised saline helps loosen secretions. Steam inhalation. Benzonatate.

The Palliative Care Network of Wisconsin notes that many patients benefit from symptomatic therapy for a distressing cough while waiting for acute therapy to work. Or they have a chronic cough—defined as lasting more than eight weeks—not amenable to treatment [10†L24-L29]. That's where opioids come in.

3.2.4 Haemoptysis

Haemoptysis is distressing. And potentially life-threatening. Palliative radiotherapy is effective for mild-to-moderate haemoptysis. Bronchial artery embolisation is the first-line intervention for massive haemoptysis in patients who are candidates for active management. Success rates exceed 90 percent for immediate control.

Tranexamic acid may be used as adjunctive therapy. Evidence is limited but growing.

Terminal haemoptysis protocol. Have a clear plan. Dark towels to reduce visual distress. Position the patient on the affected side. Intravenous or subcutaneous midazolam and opioids. Family support. Communication. Discuss the possibility in advance, especially with large central tumours.

3.2.5 Pain

Pain in pulmonary metastases may arise from chest wall invasion, rib metastases, pleural involvement, or neuropathic sources. The WHO analgesic ladder provides the framework. Paracetamol first-line. NSAIDs cautiously. Weak opioids for moderate pain. Strong opioids for severe pain.

Palliative radiotherapy is effective for localised pain. A 2025 study compared two regimens—30 Gy in 10 fractions versus 20 Gy in 5 fractions—for pain palliation in metastatic lung cancer. Both regimens offer equivalent, durable pain palliation with minimal toxicity. The shorter 20 Gy in 5 fractions regimen is preferable in advanced disease due to patient convenience and resource efficiency [9†L37-L42].

Palliative radiotherapy could achieve a significant pain response in up to 80 percent of patients with a median response duration of 18 to 21 months [9†L33-L35]. That's not trivial.

Adjuvants for neuropathic pain. Gabapentin. Pregabalin. Amitriptyline. Duloxetine. Corticosteroids for bone pain, nerve compression, and brain metastases.

3.2.6 Fatigue, Anorexia, and Cachexia

Fatigue is pervasive. It's not just tiredness. It's a bone-deep exhaustion that makes everything harder. Treat reversible causes. Anaemia. Hypothyroidism. Depression. Medication side effects. Then targeted interventions. Exercise. Energy conservation. Psychological support.

Corticosteroids have been used for symptom palliation in lung cancer. Anorexia and cachexia. Fatigue. Dyspnoea. Nausea and vomiting. Dexamethasone 4 to 8 milligrams daily can improve appetite and wellbeing for short periods [11†L12-L18]. Megestrol acetate may improve appetite but increases thromboembolic risk. Use cautiously.

3.2.7 Psychological and Existential Distress

Depression and anxiety affect a huge proportion of patients with pulmonary metastases. They worsen outcomes. They make everything worse. Screen for them. Use PHQ-9 or HADS. Treat with SSRIs when indicated. Offer cognitive behavioural therapy. Mindfulness. Support groups. Spiritual care. Chaplaincy. Meaning-making. Legacy work.

3.3 Interventional Procedures

Interventional pulmonology and interventional radiology play an increasingly important role in palliative care for pulmonary metastases. Bronchoscopic interventions for central airway obstruction provide rapid symptom relief. Laser photoresection. Argon plasma coagulation. Cryotherapy. Balloon dilatation. Tracheobronchial stents for extrinsic compression.

Endobronchial brachytherapy provides sustained relief of cough and haemoptysis in selected patients.

Interventional radiology contributes through bronchial artery embolisation for haemoptysis. Image-guided tumour ablation. These procedures should be integrated into a comprehensive palliative care plan.

3.4 Disease-Modifying Therapies in the Palliative Context

3.4.1 Stereotactic Ablative Radiotherapy (SABR)

SABR has transformed the management of oligometastatic disease. The SABR-COMET trial randomised 99 patients 2:1 to SABR for 1 to 5 metastases versus palliative standard of care [1†L49-L52]. The results were practice-changing. SABR improved overall survival.

A 2025 review in the Annals of Palliative Medicine noted that SABR is particularly effective for pulmonary metastases, achieving higher local control rates than hepatic lesions. Likely due to differences in tissue radiosensitivity. Palliative SABR has been shown to delay systemic therapy and improve symptom management, with low toxicity rates [1†L36-L40].

For patients with oligometastatic disease—1 to 3 metastases—SABR offers durable local control and symptom relief. It's not curative. But it's disease-modifying. And it can extend the chemotherapy-free interval.

3.4.2 Pulmonary Metastasectomy

Pulmonary metastasectomy is associated with comparable outcomes to liver metastasectomy when resection is complete and nodal involvement is absent [2†L7-L9]. A 2026 study found that postoperative symptom resolution was achieved in 94 percent of patients. Median follow-up was 26 months, with a median disease-free survival of 22 months [2†L11-L15].

But here's the reality check. Surgery is for selected patients. Good performance status. Limited number of metastases. Controlled primary tumour. No extrathoracic disease. For the rest, palliative care is the priority.

3.4.3 Systemic Therapy

Systemic chemotherapy or hormonal therapy is the best long-term management option for treatment-sensitive tumours [6†L37-L39]. Immunotherapy. Targeted therapy. These can improve symptoms. Extend life. But they come with toxicity. And the decision to offer them should balance benefit against burden. Patient preference matters. Some patients prioritise quality of life over survival.

3.5 Advance Care Planning

Advance care planning in pulmonary metastases is inconsistently implemented. That's a problem. It leads to end-of-life care unaligned with the patient's wishes. Increased distress. Family burden.

The German S3 guideline for lung cancer recommends advance care planning for patients with incurable lung cancer. Palliative care should be provided by qualified professionals in all relevant dimensions—physical, psychological, social, and spiritual [12†L4-L22]. Documentation matters.

Key elements. Goals of care. Values. Preferences for cardiopulmonary resuscitation and mechanical ventilation. Preferences for hospitalisation and intensive care. Views on artificial nutrition and hydration. Preferred place of care and death. Appointment of healthcare proxy. Review regularly.

3.6 End-of-Life Care

Recognising the terminal phase in pulmonary metastases can be challenging. But there are features. Progressive decline in performance status. Refractory dyspnoea at rest. Worsening cachexia. Delirium. Reduced consciousness. The patient expresses a desire for comfort-focused care.

Symptom control in the last days of life. Morphine subcutaneously for dyspnoea. Midazolam for agitation and anxiety. Glycopyrronium for respiratory secretions. Haloperidol for nausea and vomiting. Stop non-essential medications. Avoid intravenous fluids unless for comfort. Oxygen continued if it provides comfort.

The National Comprehensive Cancer Network recommends image-guided radiation therapy for local palliation or prevention of symptoms including pain, bleeding, and obstruction in advanced lung cancer [0†L37-L40]. That includes pulmonary metastases.

4. Discussion

4.1 Why Palliative Care Gets Ignored in Pulmonary Metastases

Palliative care in pulmonary metastases is underused. Why?

First, the disease trajectory is unpredictable. Unlike some cancers, where there's a clear terminal phase, pulmonary metastases can progress rapidly or smoulder for years. Clinicians struggle to know when to refer.

Second, there's a misconception that palliative care equals hospice. It doesn't. Palliative care is about symptom management and quality of life, alongside disease-directed therapy. It can start at diagnosis.

Third, there's a lack of trained palliative care clinicians. And there's a lack of oncology clinicians trained in palliative care.

Fourth, patients often don't want to talk about it. Fear. Denial. Cultural factors. These are real barriers. But they can be overcome with sensitive communication.

4.2 The SABR Revolution

SABR has changed the conversation for oligometastatic disease. The SABR-COMET trial demonstrated improved overall survival. That's not trivial. It means that for some patients, aggressive local therapy to metastases can extend life. And improve quality of life.

But SABR is not for everyone. It requires good performance status. Limited number of metastases. Adequate pulmonary reserve. And it's not curative. It's disease-modifying. Palliative. The goal is control, not cure.

4.3 The Opioid Debate

The evidence on opioids for dyspnoea in pulmonary metastases is mixed. Some studies show benefit. Others don't. A critical review argued against their use in COPD. But pulmonary metastases are different. The dyspnoea is often caused by mechanical factors—effusion, obstruction—that can be addressed. Opioids help with the sensation of breathlessness. They don't fix the underlying cause. But they make it bearable.

Individualise. Consider the patient's goals. The severity of dyspnoea. The risk of respiratory depression. The availability of non-pharmacological alternatives. Start low. Monitor closely. Have a plan for titration and de-escalation.

4.4 Malignant Pleural Effusion: A Paradigm Shift

The management of malignant pleural effusion has shifted. Indwelling pleural catheters are now preferred in many situations. They allow home drainage. Patient autonomy. And they're effective even with trapped lung. The TIME2 trial demonstrated equivalent symptom relief to talc pleurodesis with fewer hospital days.

But indwelling catheters aren't for everyone. Some patients prefer pleurodesis. Some have a short prognosis and repeated thoracentesis is appropriate. The choice should be individualised. Patient preference matters.

4.5 Gaps in Evidence

Despite advances, gaps remain. Optimal management of refractory dyspnoea. Role of SABR in different tumour types. Effectiveness of immunotherapy in symptom control. Integration of palliative care in low-resource settings. Use of telehealth for palliative care delivery. Biomarkers for prognostication and treatment selection.

Future research should focus on these areas. As well as on implementation science. To ensure evidence-based palliative care reaches all patients who need it.

5. Conclusion

Palliative care in pulmonary metastases is not optional. It's essential. The symptom burden is enormous. The psychological burden is enormous. And the current system isn't meeting the need.

The evidence supports early integration. The ASCO guidelines recommend it. The patients need it. But implementation lags.

Start early. Use a needs-based approach. Address symptoms. Support families. Plan for the end. It's not complicated in principle. It's just hard in practice.

References

1. Le Péchoux C. Radiotherapy for lung metastases. Cancer Radiother. 2025;29(7-8):xxx-xxx. doi:10.1016/j.canrad.2025.09.003

2. Extended Indications for Sleeve Lobectomy: A Single-Center Experience of Surgical Management of Central Pulmonary Metastases. Ovid. 2026.

3. Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer. Endocr Connect. 2025;14(11):xxx-xxx. doi:10.1530/EC-25-xxxx

4. Opioids for Cough. Palliative Care Network of Wisconsin. Fast Fact #xxx. Updated October 24, 2024. https://www.mypcnow.org

5. Mitchell C, Kalar RS, Hsu ML. Individualized approach to palliative care integration for patients with metastatic non-small cell lung cancer. Front Med. 2026;13:1921610. doi:10.3389/fmed.2026.1921610

6. Thai V, Damant R. Malignant Pleural Effusions: Interventional Management. Palliative Care Network of Wisconsin. Fast Fact #157. Published October 23, 2025. https://www.mypcnow.org/fast-fact/malignant-pleural-effusions-interventional-management/

7. Management of Dyspnea in Metastatic Non-Small Cell Lung Cancer. Praxismed. Updated December 22, 2025. https://praxismed.org/article/deba2744-31a6-4c8b-a7aa-cb6056e3d2e9

8. Comparative Evaluation of Pain Relief in Metastatic Lung Cancer Using Two Palliative Radiotherapy Schedules: A Prospective Observational Study. J Pharm Technol. 2025;xxx(xxx):xxx-xxx. doi:10.xxxx/jptcp.2025.xxxx

9. Corticosteroids in lung cancer. Remedy. 2025. https://remedy.med.bg.ac.rs

10. Leitlinienprogramm Onkologie. Lungenkarzinom, Langversion 4.0. April 2025. https://www.leitlinienprogramm-onkologie.de

Prepared By: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Copyright: © 2026 Dr. Shekhar Ingle and Team, Doctor's Forum for All. All rights reserved.

Date: 2026